2011
DOI: 10.1093/eurheartj/ehr218
|View full text |Cite
|
Sign up to set email alerts
|

ESC Guidelines on the management of cardiovascular diseases during pregnancy: The Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC)

Abstract: The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to Oxford University Press, the publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC. Disclaimer. The ESC Guidelines… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

5
757
2
57

Year Published

2015
2015
2023
2023

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 1,383 publications
(823 citation statements)
references
References 250 publications
5
757
2
57
Order By: Relevance
“…The current guidelines for AF recommend the use of digoxin, nondihydropyridine calcium‐channel antagonists, or beta‐blockers for AF 6, 13. Perhaps because of concern for fetal toxicity, many patients were not maintained on any medications during their pregnancies.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…The current guidelines for AF recommend the use of digoxin, nondihydropyridine calcium‐channel antagonists, or beta‐blockers for AF 6, 13. Perhaps because of concern for fetal toxicity, many patients were not maintained on any medications during their pregnancies.…”
Section: Discussionmentioning
confidence: 99%
“…Organogenesis occurs during the first trimester, and the developing fetus is sensitive to potential teratogenic effects of medications. In the second and third trimesters, medications may have potential effects on fetal growth or lead to fetal arrhythmias 13. Many commonly used medications in AF, such as warfarin and some beta‐blockers, have been shown to increase the risks of adverse fetal outcomes 14, 15, 16, 17.…”
Section: Introductionmentioning
confidence: 99%
“…10 Further information was collected on prior surgical repair and re-operation, pre-pregnancy haemodynamic status was assessed by echocardiography, cardiac magnetic resonance and clinical reports, and the NYHA functional class pre-pregnancy was ascertained. 11 Adverse cardiac events were classified as cardiac complications as follows: maternal cardiac death, pulmonary oedema (documented on physical examination or radiography), treated arrhythmia (RT, sustained arrhythmia requiring treatment), venous thrombosis, arterial thrombosis, valve thrombosis, endocarditis, reduced NYHA functional class from baseline, invasive treatment (invasive cardiac intervention during pregnancy or within 6 months of delivery) and arrhythmia not treated (RNT, unsustained arrhythmia not requiring treatment).…”
Section: Methodsmentioning
confidence: 99%
“…In 2011, the ACC/AHA published updated guidelines for the prevention of CVD in women that now include pregnancy history, including GH and preeclampsia, in the CVD risk assessment algorithm 74. The European Society of Cardiology and the National Institute for Health and Care Excellence also have guidelines for the management of arterial hypertension that discuss the need to recognize long‐term cardiovascular consequences of HDP 75, 76…”
Section: Current Guidelines and Recommendationsmentioning
confidence: 99%